{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T03:57:29Z","timestamp":1793591849846,"version":"4.5.0"},"reference-count":343,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Health Research Institute grant","doi-asserted-by":"crossref","award":["NHRI-EX114-11212BI"],"award-info":[{"award-number":["NHRI-EX114-11212BI"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taiwan Ministry of Science and Technology grant","award":["MOST-109-2327-B-006-004"],"award-info":[{"award-number":["MOST-109-2327-B-006-004"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoints play pivotal roles in regulating immune responses and maintaining tolerance. In cancer, these molecules are hijacked to suppress antitumor immunity, resulting in therapeutic resistance to immune checkpoint blockade (ICB). Recent advances have highlighted the critical role of post-translational modifications (PTMs), including phosphorylation, ubiquitination, glycosylation, palmitoylation, UFMylation, acetylation, SUMOylation, methylation, and ISGylation, in modulating checkpoint stability, trafficking, and function across diverse immune and tumor cell types. These dynamic PTMs reshape the tumor microenvironment (TME) by controlling immune cell function, antigen presentation, and inflammatory signaling. This review comprehensively outlines the mechanistic contributions of PTMs to immune checkpoint regulation, emphasizing how these PTMs orchestrate immune evasion and clinical outcomes. Special focus is given to PTMs of PD-L1, PD-1, TIM-3, TIGIT, CTLA-4, LAG-3, VISTA, BTLA, and SIRP\u03b1. We also discuss how targeting PTM-regulating enzymes or specific modification motifs offers a promising therapeutic strategy to overcome ICB resistance. Understanding the PTMs landscape provides critical insight into resistance mechanisms and unveils promising opportunities for rational combination therapies aimed at reprogramming the immunosuppressive TME and enhancing antitumor immunity.<\/jats:p>","DOI":"10.1186\/s12929-025-01202-1","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T08:05:27Z","timestamp":1767513927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications"],"prefix":"10.1186","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1782-6783","authenticated-orcid":false,"given":"Hung-Chia","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1017-4230","authenticated-orcid":false,"given":"Lun-Ling","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-2067","authenticated-orcid":false,"given":"Yi-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"issue":"3","key":"1202_CR1","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"10","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12(10):2575\u201387. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04224.x.","journal-title":"Am J Transplant"},{"issue":"8","key":"1202_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"GR Kim","year":"2022","unstructured":"Kim GR, Choi JM. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells. 2022;45(8):513\u201321. https:\/\/doi.org\/10.14348\/molcells.2022.2056.","journal-title":"Mol Cells"},{"issue":"1","key":"1202_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000911","volume":"8","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. https:\/\/doi.org\/10.1136\/jitc-2020-000911.","journal-title":"J Immunother Cancer"},{"key":"1202_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42:101305. https:\/\/doi.org\/10.1016\/j.smim.2019.101305.","journal-title":"Semin Immunol"},{"issue":"5","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP\u03b1 immune checkpoint. Immunity. 2020;52(5):742\u201352.","journal-title":"Immunity"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-immunol-030409-101202","volume":"28","author":"TL Murphy","year":"2010","unstructured":"Murphy TL, Murphy KM. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol. 2010;28:389\u2013411.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1202_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20.","journal-title":"Mol Cancer"},{"issue":"1","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1202_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. https:\/\/doi.org\/10.1038\/ncomms10501.","journal-title":"Nat Commun"},{"issue":"4","key":"1202_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1564505","volume":"8","author":"E Limagne","year":"2019","unstructured":"Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, et al. Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019;8(4):e1564505. https:\/\/doi.org\/10.1080\/2162402X.2018.1564505.","journal-title":"Oncoimmunology"},{"issue":"16","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024;187(16):4373-4388.e15. https:\/\/doi.org\/10.1016\/j.cell.2024.06.036.","journal-title":"Cell"},{"issue":"1","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"10","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","volume":"1864","author":"A Drazic","year":"2016","unstructured":"Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. Biochim Biophys Acta. 2016;1864(10):1372\u2013401. https:\/\/doi.org\/10.1016\/j.bbapap.2016.06.007.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1202_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/BJ20100158","volume":"428","author":"KA Wilkinson","year":"2010","unstructured":"Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J. 2010;428(2):133\u201345. https:\/\/doi.org\/10.1042\/BJ20100158.","journal-title":"Biochem J"},{"key":"1202_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216080","volume":"556","author":"HM Nguyen","year":"2023","unstructured":"Nguyen HM, Gaikwad S, Oladejo M, Agrawal MY, Srivastava SK, Wood LM. Interferon stimulated gene 15 (ISG15) in cancer: an update. Cancer Lett. 2023;556:216080. https:\/\/doi.org\/10.1016\/j.canlet.2023.216080.","journal-title":"Cancer Lett"},{"issue":"1","key":"1202_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-025-00627-6","volume":"14","author":"Q Hu","year":"2025","unstructured":"Hu Q, Shi Y, Wang H, Bing L, Xu Z. Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy. Exp Hematol Oncol. 2025;14(1):37.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"1202_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, et al. Expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(7):681\u201391.","journal-title":"Nat Cancer"},{"issue":"1","key":"1202_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101377","volume":"5","author":"J Sprooten","year":"2024","unstructured":"Sprooten J, Vanmeerbeek I, Datsi A, Govaerts J, Naulaerts S, Laureano RS, et al. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. Cell Rep Med. 2024;5(1):101377. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101377.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1202_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101420","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep Med. 2024;5(2):101420. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101420.","journal-title":"Cell Rep Med"},{"issue":"4","key":"1202_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1413520","volume":"7","author":"M Shen","year":"2018","unstructured":"Shen M, Wang J, Yu W, Zhang C, Liu M, Wang K, et al. A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. Oncoimmunology. 2018;7(4):e1413520. https:\/\/doi.org\/10.1080\/2162402X.2017.1413520.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1202_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6997","volume":"6","author":"AR Khan","year":"2015","unstructured":"Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6(1):5997. https:\/\/doi.org\/10.1038\/ncomms6997.","journal-title":"Nat Commun"},{"issue":"2","key":"1202_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103785","volume":"25","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Han L, Chen Z, Li Y, Zhou B, Hu R, et al. PD-L1+CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance. iScience. 2022;25(2):103785.","journal-title":"iScience"},{"issue":"1","key":"1202_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05047-1","volume":"9","author":"L Brochez","year":"2018","unstructured":"Brochez L, Meireson A, Chevolet I, Sundahl N, Ost P, Kruse V. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat Commun. 2018;9(1):2921. https:\/\/doi.org\/10.1038\/s41467-018-05047-1.","journal-title":"Nat Commun"},{"key":"1202_CR26","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"issue":"1","key":"1202_CR27","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41467-021-22467-8","volume":"12","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 2021;12(1):2346.","journal-title":"Nat Commun"},{"issue":"11","key":"1202_CR28","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.molcel.2021.03.037","volume":"81","author":"X Dai","year":"2021","unstructured":"Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81(11):2317-2331.e6. https:\/\/doi.org\/10.1016\/j.molcel.2021.03.037.","journal-title":"Mol Cell"},{"issue":"4","key":"1202_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606-620.e7. https:\/\/doi.org\/10.1016\/j.molcel.2018.07.030.","journal-title":"Mol Cell"},{"issue":"8","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129(8):3324\u201338. https:\/\/doi.org\/10.1172\/JCI126022.","journal-title":"J Clin Invest"},{"issue":"11","key":"1202_CR31","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/0008-5472.CAN-21-2300","volume":"82","author":"X Zhao","year":"2022","unstructured":"Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, et al. Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. Cancer Res. 2022;82(11):2185\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2300.","journal-title":"Cancer Res"},{"issue":"10","key":"1202_CR32","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.ymthe.2023.07.021","volume":"31","author":"K Sun","year":"2023","unstructured":"Sun K, Zhang X, Lao M, He L, Wang S, Yang H, et al. Targeting leucine-rich repeat serine\/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Mol Ther. 2023;31(10):2929\u201347. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.021.","journal-title":"Mol Ther"},{"issue":"1","key":"1202_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-023-01883-y","volume":"22","author":"Z Miao","year":"2023","unstructured":"Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang X, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375\/PRKDC axis and PD-L1 phosphorylation. Mol Cancer. 2023;22(1):205.","journal-title":"Mol Cancer"},{"issue":"7686","key":"1202_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91\u20135.","journal-title":"Nature"},{"issue":"10","key":"1202_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003404","volume":"8","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde dehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression. Adv Sci. 2021;8(10):2003404. https:\/\/doi.org\/10.1002\/advs.202003404.","journal-title":"Adv Sci"},{"issue":"9","key":"1202_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007313","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zeng L, Wang M, Yang Z, Zhang H, Gao L, et al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. J Immunother Cancer. 2023;11(9):e007313. https:\/\/doi.org\/10.1136\/jitc-2023-007313.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1202_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154754","volume":"133","author":"L Ding","year":"2023","unstructured":"Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, et al. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. 2023;133(1):e154754. https:\/\/doi.org\/10.1172\/JCI154754.","journal-title":"J Clin Invest"},{"issue":"1","key":"1202_CR38","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13(1):6951.","journal-title":"Nat Commun"},{"issue":"1","key":"1202_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82(1):114\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2362.","journal-title":"Cancer Res"},{"issue":"2","key":"1202_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41419-024-06563-3","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Shi D, Li S, Shi X, Liu Y, Zhang Y, et al. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death Dis. 2024;15(2):175.","journal-title":"Cell Death Dis"},{"key":"1202_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100850","volume":"35","author":"Y Gao","year":"2023","unstructured":"Gao Y, Zou T, Xu P, Wang Y, Jiang Y, Chen YX, et al. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. Neoplasia. 2023;35:100850. https:\/\/doi.org\/10.1016\/j.neo.2022.100850.","journal-title":"Neoplasia"},{"issue":"6","key":"1202_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12033-022-00587-w","volume":"65","author":"C Jiang","year":"2023","unstructured":"Jiang C, He L, Xiao S, Wu W, Zhao Q, Liu F. E3 ubiquitin ligase RNF125 suppresses immune escape in head and neck squamous cell carcinoma by regulating PD-L1 expression. Mol Biotechnol. 2023;65(6):891\u2013903.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"1202_CR43","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41467-023-37617-3","volume":"14","author":"J Yi","year":"2023","unstructured":"Yi J, Tavana O, Li H, Wang D, Baer RJ, Gu W. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. Nat Commun. 2023;14(1):1941.","journal-title":"Nat Commun"},{"issue":"2","key":"1202_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001866","volume":"8","author":"W Guo","year":"2020","unstructured":"Guo W, Ma J, Guo S, Wang H, Wang S, Shi Q, et al. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma. J Immunother Cancer. 2020;8(2):e001866. https:\/\/doi.org\/10.1136\/jitc-2020-001866.","journal-title":"J Immunother Cancer"},{"issue":"7670","key":"1202_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106\u201310.","journal-title":"Nature"},{"issue":"10","key":"1202_CR46","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1158\/1541-7786.MCR-21-0147","volume":"19","author":"G Qian","year":"2021","unstructured":"Qian G, Guo J, Vallega KA, Hu C, Chen Z, Deng Y, et al. Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. Mol Cancer Res. 2021;19(10):1622\u201334. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0147.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"1202_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160456","volume":"133","author":"X Yu","year":"2023","unstructured":"Yu X, Li W, Liu H, Wang X, Coarfa C, Cheng C, et al. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023;133(3):e160456. https:\/\/doi.org\/10.1172\/JCI160456.","journal-title":"J Clin Invest"},{"issue":"12","key":"1202_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009444","volume":"12","author":"L Lv","year":"2024","unstructured":"Lv L, Miao Q, Zhan S, Chen P, Liu W, Lv J, et al. LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. J Immunother Cancer. 2024;12(12):e009444. https:\/\/doi.org\/10.1136\/jitc-2024-009444.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1202_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925\u201339.","journal-title":"Cancer Cell"},{"issue":"8","key":"1202_CR50","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/cam4.1675","volume":"7","author":"W Jingjing","year":"2018","unstructured":"Jingjing W, Wenzheng G, Donghua W, Guangyu H, Aiping Z, Wenjuan W. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 2018;7(8):4004\u201311. https:\/\/doi.org\/10.1002\/cam4.1675.","journal-title":"Cancer Med"},{"issue":"1","key":"1202_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00612-y","volume":"18","author":"Y Wang","year":"2020","unstructured":"Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S, et al. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 2020;18(1):112. https:\/\/doi.org\/10.1186\/s12964-020-00612-y.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"1202_CR52","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.apsb.2020.11.005","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang Z, Kang W, Li O, Qi F, Wang J, You Y, et al. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B. 2021;11(3):694\u2013707. https:\/\/doi.org\/10.1016\/j.apsb.2020.11.005.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"1202_CR53","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","volume":"30","author":"Z Kuang","year":"2023","unstructured":"Kuang Z, Liu X, Zhang N, Dong J, Sun C, Yin M, et al. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1. Cell Death Differ. 2023;30(10):2249\u201364. https:\/\/doi.org\/10.1038\/s41418-023-01219-9.","journal-title":"Cell Death Differ"},{"issue":"6","key":"1202_CR54","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","volume":"28","author":"D Zhu","year":"2021","unstructured":"Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021;28(6):1773\u201389. https:\/\/doi.org\/10.1038\/s41418-020-00700-z.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1202_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01805-5","volume":"22","author":"M Fu","year":"2024","unstructured":"Fu M, Li J, Xuan Z, Zheng Z, Liu Y, Zhang Z, et al. NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10. Cell Commun Signal. 2024;22(1):429. https:\/\/doi.org\/10.1186\/s12964-024-01805-5.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"1202_CR56","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41418-024-01277-7","volume":"31","author":"MJ Young","year":"2024","unstructured":"Young MJ, Wang SA, Chen YC, Liu CY, Hsu KC, Tang SW, et al. USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy. Cell Death Differ. 2024;31(5):574\u201391.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1202_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187-201.e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"1202_CR58","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908.","journal-title":"Nat Commun"},{"issue":"1","key":"1202_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-023-02758-2","volume":"42","author":"D Wang","year":"2023","unstructured":"Wang D, Wu S, He J, Sun L, Zhu H, Zhang Y, et al. FAT4 overexpression promotes antitumor immunity by regulating the \u03b2-catenin\/STT3\/PD-L1 axis in cervical cancer. J Exp Clin Cancer Res. 2023;42(1):222.","journal-title":"J Exp Clin Cancer Res"},{"key":"1202_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.815437","volume":"12","author":"XM Ma","year":"2022","unstructured":"Ma XM, Luo YF, Zeng FF, Su C, Liu X, Li XP, et al. TGF-\u03b21-mediated PD-L1 glycosylation contributes to immune escape via c-Jun\/STT3A pathway in nasopharyngeal carcinoma. Front Oncol. 2022;12:815437. https:\/\/doi.org\/10.3389\/fonc.2022.815437.","journal-title":"Front Oncol"},{"issue":"12","key":"1202_CR61","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.jtha.2023.08.008","volume":"21","author":"S Paul","year":"2023","unstructured":"Paul S, Das K, Ghosh A, Chatterjee A, Bhoumick A, Basu A, et al. Coagulation factor VIIa enhances programmed death-ligand 1 expression and its stability in breast cancer cells to promote breast cancer immune evasion. J Thromb Haemost. 2023;21(12):3522\u201338. https:\/\/doi.org\/10.1016\/j.jtha.2023.08.008.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1202_CR62","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/1878-0261.12664","volume":"14","author":"X Liu","year":"2020","unstructured":"Liu X, Zhang Y, Han Y, Lu W, Yang J, Tian J, et al. Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma. Mol Oncol. 2020;14(5):1028\u201344. https:\/\/doi.org\/10.1002\/1878-0261.12664.","journal-title":"Mol Oncol"},{"issue":"1","key":"1202_CR63","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-023-02711-3","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. J Exp Clin Cancer Res. 2023;42(1):146.","journal-title":"J Exp Clin Cancer Res"},{"key":"1202_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111942","volume":"134","author":"S Chong","year":"2025","unstructured":"Chong S, Liu Y, Bian Z, Hu D, Guo S, Dong C, et al. GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma. Cell Signal. 2025;134:111942. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111942.","journal-title":"Cell Signal"},{"issue":"628","key":"1202_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3072","volume":"14","author":"B Greco","year":"2022","unstructured":"Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med. 2022;14(628):eabg3072.","journal-title":"Sci Transl Med"},{"issue":"32","key":"1202_CR66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303400120","volume":"120","author":"K Zeng","year":"2023","unstructured":"Zeng K, Zeng Y, Zhan H, Zhan Z, Wang L, Xie Y, et al. SEC61G assists EGFR-amplified glioblastoma to evade immune elimination. Proc Natl Acad Sci U S A. 2023;120(32):e2303400120. https:\/\/doi.org\/10.1073\/pnas.2303400120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1202_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3659714","volume":"2022","author":"X Duan","year":"2022","unstructured":"Duan X, Xie Y, Yu J, Hu X, Liu Z, Li N, et al. MCT4\/lactate promotes PD-L1 glycosylation in triple-negative breast cancer cells. J Oncol. 2022;2022:3659714. https:\/\/doi.org\/10.1155\/2022\/3659714.","journal-title":"J Oncol"},{"issue":"3","key":"1202_CR68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/glycob\/cwad005","volume":"33","author":"K Cai","year":"2023","unstructured":"Cai K, Chen Q, Shi D, Huang S, Wang C, Ai Z, et al. Sialylation-dependent interaction between PD-L1 and CD169 promotes monocyte adhesion to endothelial cells. Glycobiology. 2023;33(3):215\u201324. https:\/\/doi.org\/10.1093\/glycob\/cwad005.","journal-title":"Glycobiology"},{"key":"1202_CR69","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.48916","volume":"8","author":"R Singh","year":"2019","unstructured":"Singh R, Choi BK. Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis. Elife. 2019;8:e48916. https:\/\/doi.org\/10.7554\/eLife.48916.","journal-title":"Elife"},{"issue":"1","key":"1202_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113641","volume":"43","author":"WC Chou","year":"2024","unstructured":"Chou WC, Chen WT, Kuo CT, Chang YM, Lu YS, Li CW, et al. Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer. Cell Rep. 2024;43(1):113641. https:\/\/doi.org\/10.1016\/j.celrep.2023.113641.","journal-title":"Cell Rep"},{"issue":"4","key":"1202_CR71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3(4):306\u201317.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"1202_CR72","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29(1):83\u20136.","journal-title":"Cell Res"},{"issue":"8","key":"1202_CR73","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1021\/acs.langmuir.4c04441","volume":"41","author":"S Zhang","year":"2025","unstructured":"Zhang S, Wang HY, Tao X, Chen Z, Levental I, Lin X. Palmitoylation of PD-L1 regulates its membrane orientation and immune evasion. Langmuir. 2025;41(8):5170\u20138.","journal-title":"Langmuir"},{"issue":"11","key":"1202_CR74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215732120","volume":"120","author":"J Zhou","year":"2023","unstructured":"Zhou J, Ma X, He X, Chen B, Yuan J, Jin Z, et al. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target. Proc Natl Acad Sci U S A. 2023;120(11):e2215732120. https:\/\/doi.org\/10.1073\/pnas.2215732120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1202_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00766-4","volume":"14","author":"MA Romeo","year":"2023","unstructured":"Romeo MA, Gilardini Montani MS, Santarelli R, Benedetti R, Arena A, Cirone M. Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1. Discov Oncol. 2023;14(1):152. https:\/\/doi.org\/10.1007\/s12672-023-00766-4.","journal-title":"Discov Oncol"},{"issue":"9","key":"1202_CR76","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064\u201375. https:\/\/doi.org\/10.1038\/s41556-020-0562-4.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1202_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8(1):246. https:\/\/doi.org\/10.1038\/s41392-023-01450-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"1202_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade4186","volume":"9","author":"C Huang","year":"2023","unstructured":"Huang C, Ren S, Chen Y, Liu A, Wu Q, Jiang T, et al. PD-L1 methylation restricts PD-L1\/PD-1 interactions to control cancer immune surveillance. Sci Adv. 2023;9(21):eade4186.","journal-title":"Sci Adv"},{"issue":"1","key":"1202_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04135-1","volume":"21","author":"T Qu","year":"2023","unstructured":"Qu T, Zhang W, Yan C, Ren D, Wang Y, Guo Y, et al. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma. J Transl Med. 2023;21(1):341. https:\/\/doi.org\/10.1186\/s12967-023-04135-1.","journal-title":"J Transl Med"},{"issue":"1","key":"1202_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03074-z","volume":"43","author":"SC Pitts","year":"2024","unstructured":"Pitts SC, Schlom J, Donahue RN. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. J Exp Clin Cancer Res. 2024;43(1):155. https:\/\/doi.org\/10.1186\/s13046-024-03074-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1202_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1744980","volume":"9","author":"JJ Orme","year":"2020","unstructured":"Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020;9(1):1744980. https:\/\/doi.org\/10.1080\/2162402X.2020.1744980.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1202_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1091146","volume":"5","author":"C Dezutter-Dambuyant","year":"2015","unstructured":"Dezutter-Dambuyant C, Durand I, Alberti L, Bendriss-Vermare N, Valladeau-Guilemond J, Duc A, et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. Oncoimmunology. 2015;5(3):e1091146. https:\/\/doi.org\/10.1080\/2162402X.2015.1091146.","journal-title":"Oncoimmunology"},{"issue":"2","key":"1202_CR83","first-page":"379","volume":"52","author":"M Hira-Miyazawa","year":"2018","unstructured":"Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, et al. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol. 2018;52(2):379\u201388.","journal-title":"Int J Oncol"},{"issue":"2","key":"1202_CR84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/fon-2021-0641","volume":"18","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Wang C, Wang Y, Dai L. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. Future Oncol. 2022;18(2):261\u201373. https:\/\/doi.org\/10.2217\/fon-2021-0641.","journal-title":"Future Oncol"},{"issue":"1","key":"1202_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99311-y","volume":"11","author":"SY Oh","year":"2021","unstructured":"Oh SY, Kim S, Keam B, Kim TM, Kim DW, Heo DS. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021;11(1):19712. https:\/\/doi.org\/10.1038\/s41598-021-99311-y.","journal-title":"Sci Rep"},{"issue":"6","key":"1202_CR86","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10120-023-01429-7","volume":"26","author":"M Chivu-Economescu","year":"2023","unstructured":"Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A, et al. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients. Gastric Cancer. 2023;26(6):934\u201346.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1202_CR87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12967-023-03879-0","volume":"21","author":"Y He","year":"2023","unstructured":"He Y, Zhang X, Zhu M, He W, Hua H, Ye F, et al. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. J Transl Med. 2023;21(1):25.","journal-title":"J Transl Med"},{"issue":"5","key":"1202_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85935","volume":"1","author":"DE Lowther","year":"2016","unstructured":"Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935. https:\/\/doi.org\/10.1172\/jci.insight.85935.","journal-title":"JCI Insight"},{"issue":"7","key":"1202_CR89","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41590-025-02172-0","volume":"26","author":"JX Lim","year":"2025","unstructured":"Lim JX, McTaggart T, Jung SK, Smith KJ, Hulme G, Laba S, et al. PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma. Nat Immunol. 2025;26(7):1074\u201386.","journal-title":"Nat Immunol"},{"issue":"20","key":"1202_CR90","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999\u201310008.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7655","key":"1202_CR91","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139. https:\/\/doi.org\/10.1038\/nature22396.","journal-title":"Nature"},{"issue":"3","key":"1202_CR92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1085146","volume":"5","author":"TS Lim","year":"2015","unstructured":"Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology. 2015;5(3):e1085146. https:\/\/doi.org\/10.1080\/2162402X.2015.1085146.","journal-title":"Oncoimmunology"},{"issue":"8","key":"1202_CR93","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41375-024-02271-1","volume":"38","author":"M Farhat","year":"2024","unstructured":"Farhat M, Croft W, Parry HM, Verma K, Kinsella FAM, Xu J, et al. PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL. Leukemia. 2024;38(8):1813\u20137. https:\/\/doi.org\/10.1038\/s41375-024-02271-1.","journal-title":"Leukemia"},{"issue":"44","key":"1202_CR94","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353. https:\/\/doi.org\/10.1038\/onc.2017.209.","journal-title":"Oncogene"},{"issue":"5","key":"1202_CR95","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","volume":"6","author":"X Xiao","year":"2016","unstructured":"Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, et al. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016;6(5):546\u201359.","journal-title":"Cancer Discov"},{"issue":"38","key":"1202_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):eabd2712.","journal-title":"Sci Adv"},{"issue":"1","key":"1202_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53463-0","volume":"9","author":"K Bardhan","year":"2019","unstructured":"Bardhan K, Aksoylar HI, Le Bourgeois T, Strauss L, Weaver JD, Delcuze B, et al. Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Sci Rep. 2019;9(1):17252. https:\/\/doi.org\/10.1038\/s41598-019-53463-0.","journal-title":"Sci Rep"},{"issue":"12","key":"1202_CR98","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/2326-6066.CIR-21-0493","volume":"9","author":"X Bu","year":"2021","unstructured":"Bu X, Juneja VR, Reynolds CG, Mahoney KM, Bu MT, McGuire KA, et al. Monitoring PD-1 phosphorylation to evaluate PD-1 signaling during antitumor immune responses. Cancer Immunol Res. 2021;9(12):1465\u201375. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0493.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"1202_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005116","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Wei L, Hu N, Wang D, Ni J, Zhang S, et al. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2022;10(9):e005116. https:\/\/doi.org\/10.1136\/jitc-2022-005116.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1202_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38605-3","volume":"14","author":"X Xiao","year":"2023","unstructured":"Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 2023;14(1):2859. https:\/\/doi.org\/10.1038\/s41467-023-38605-3.","journal-title":"Nat Commun"},{"issue":"7734","key":"1202_CR101","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","volume":"564","author":"X Meng","year":"2018","unstructured":"Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 2018;564(7734):130\u20135.","journal-title":"Nature"},{"issue":"45","key":"1202_CR102","doi-asserted-by":"publisher","first-page":"28239","DOI":"10.1073\/pnas.2004570117","volume":"117","author":"XA Zhou","year":"2020","unstructured":"Zhou XA, Zhou J, Zhao L, Yu G, Zhan J, Shi C, et al. KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proc Natl Acad Sci U S A. 2020;117(45):28239\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1202_CR103","doi-asserted-by":"publisher","first-page":"20257","DOI":"10.1038\/s41598-019-56208-1","volume":"9","author":"C Lyle","year":"2019","unstructured":"Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, et al. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019;9(1):20257.","journal-title":"Sci Rep"},{"issue":"7","key":"1202_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112693","volume":"42","author":"Z Wu","year":"2023","unstructured":"Wu Z, Cao Z, Yao H, Yan X, Xu W, Zhang M, et al. Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2. Cell Rep. 2023;42(7):112693. https:\/\/doi.org\/10.1016\/j.celrep.2023.112693.","journal-title":"Cell Rep"},{"issue":"3","key":"1202_CR105","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, Zhang Z, Chen HY, Yao Y, Ke S, Yu K, et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol Ther. 2025;33(3):1073\u201390. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.047.","journal-title":"Mol Ther"},{"issue":"16","key":"1202_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt4258","volume":"11","author":"HC Hsieh","year":"2025","unstructured":"Hsieh HC, Young MJ, Chen KY, Su WC, Lin CC, Yen YT, et al. Deubiquitinase USP24 activated by IL-6\/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response. Sci Adv. 2025;11(16):eadt4258.","journal-title":"Sci Adv"},{"issue":"1","key":"1202_CR107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-024-01009-6","volume":"31","author":"WT Kuo","year":"2024","unstructured":"Kuo WT, Kuo IY, Hsieh HC, Wu ST, Su WC, Wang YC. Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer. J Biomed Sci. 2024;31(1):20.","journal-title":"J Biomed Sci"},{"issue":"11","key":"1202_CR108","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133","volume":"80","author":"L Sun","year":"2020","unstructured":"Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, et al. Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 2020;80(11):2298\u2013310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3133.","journal-title":"Cancer Res"},{"issue":"12","key":"1202_CR109","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051444","volume":"21","author":"K Liu","year":"2020","unstructured":"Liu K, Tan S, Jin W, Guan J, Wang Q, Sun H, et al. N-glycosylation of PD-1 promotes binding of camrelizumab. EMBO Rep. 2020;21(12):e51444. https:\/\/doi.org\/10.15252\/embr.202051444.","journal-title":"EMBO Rep"},{"issue":"5","key":"1202_CR110","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","volume":"20","author":"M Okada","year":"2017","unstructured":"Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, et al. Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 2017;20(5):1017\u201328. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.027.","journal-title":"Cell Rep"},{"issue":"1","key":"1202_CR111","doi-asserted-by":"publisher","first-page":"9631","DOI":"10.1038\/s41598-023-36203-3","volume":"13","author":"P Tit-Oon","year":"2023","unstructured":"Tit-Oon P, Wonglangka A, Boonkanta K, Ruchirawat M, Fuangthong M, Sasisekharan R, et al. Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein. Sci Rep. 2023;13(1):9631.","journal-title":"Sci Rep"},{"issue":"5","key":"1202_CR112","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1002\/jcp.30122","volume":"236","author":"J Jin","year":"2021","unstructured":"Jin J, Zhi X, Wang X, Meng D. Protein palmitoylation and its pathophysiological relevance. J Cell Physiol. 2021;236(5):3220\u201333. https:\/\/doi.org\/10.1002\/jcp.30122.","journal-title":"J Cell Physiol"},{"issue":"1","key":"1202_CR113","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1039\/D0CB00157K","volume":"2","author":"H Yao","year":"2020","unstructured":"Yao H, Li C, He F, Song T, Brosseau JP, Wang H, et al. A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC Chem Biol. 2020;2(1):192\u2013205.","journal-title":"RSC Chem Biol"},{"issue":"6","key":"1202_CR114","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.molcel.2024.01.024","volume":"84","author":"C He","year":"2024","unstructured":"He C, Xing X, Chen HY, Gao M, Shi J, Xiang B, et al. UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Mol Cell. 2024;84(6):1120-1138.e8. https:\/\/doi.org\/10.1016\/j.molcel.2024.01.024.","journal-title":"Mol Cell"},{"issue":"10","key":"1202_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101888","volume":"16","author":"M Sakuma","year":"2024","unstructured":"Sakuma M, Katagata M, Okayama H, Nakajima S, Saito K, Sato T, et al. TIM-3 expression on dendritic cells in colorectal cancer. Cancers (Basel). 2024;16(10):1888. https:\/\/doi.org\/10.3390\/cancers16101888.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1202_CR116","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"key":"1202_CR117","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","volume":"10","author":"S Kandel","year":"2021","unstructured":"Kandel S, Adhikary P, Li G, Cheng K. The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett. 2021;10:67\u201378.","journal-title":"Cancer Lett"},{"issue":"1","key":"1202_CR118","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832.","journal-title":"Nat Commun"},{"issue":"7534","key":"1202_CR119","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","volume":"517","author":"YH Huang","year":"2015","unstructured":"Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386\u201390.","journal-title":"Nature"},{"issue":"2","key":"1202_CR120","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/imm.13488","volume":"168","author":"S Yu","year":"2023","unstructured":"Yu S, Ren X, Meng F, Guo X, Tao J, Zhang W, et al. TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. Immunology. 2023;168(2):273\u201389.","journal-title":"Immunology"},{"key":"1202_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107458","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang L, Guo H, Kong S, Li W, He Q, et al. The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells. Pharmacol Res. 2024;209:107458. https:\/\/doi.org\/10.1016\/j.phrs.2024.107458.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1202_CR122","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342. https:\/\/doi.org\/10.1038\/ni.2376.","journal-title":"Nat Immunol"},{"issue":"6","key":"1202_CR123","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","volume":"54","author":"\u00c1 de Mingo Pulido","year":"2021","unstructured":"de Mingo Pulido \u00c1, H\u00e4nggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54(6):1154-1167.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.019.","journal-title":"Immunity"},{"issue":"9","key":"1202_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094332","volume":"26","author":"S Chen","year":"2025","unstructured":"Chen S, Chen J, Kong Y, Li H, Chen Z, Luo L, et al. Knockdown of TIM3 hampers dendritic cell maturation and induces immune suppression by modulating T-cell responses. Int J Mol Sci. 2025;26(9):4332. https:\/\/doi.org\/10.3390\/ijms26094332.","journal-title":"Int J Mol Sci"},{"key":"1202_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00229","volume":"7","author":"R Oca\u00f1a-Guzman","year":"2016","unstructured":"Oca\u00f1a-Guzman R, Torre-Bouscoulet L, Sada-Ovalle I. TIM-3 regulates distinct functions in macrophages. Front Immunol. 2016;7:229. https:\/\/doi.org\/10.3389\/fimmu.2016.00229.","journal-title":"Front Immunol"},{"issue":"20","key":"1202_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204943","volume":"15","author":"M Katagata","year":"2023","unstructured":"Katagata M, Okayama H, Nakajima S, Saito K, Sato T, Sakuma M, et al. TIM-3 expression and M2 polarization of macrophages in the TGF\u03b2-activated tumor microenvironment in colorectal cancer. Cancers (Basel). 2023;15(20):4943.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1202_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105329","volume":"25","author":"Q Guo","year":"2022","unstructured":"Guo Q, Shen S, Guan G, Zhu C, Zou C, Cao J, et al. Cancer cell intrinsic TIM-3 induces glioblastoma progression. iScience. 2022;25(11):105329.","journal-title":"iScience"},{"issue":"1","key":"1202_CR128","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","volume":"17","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Li Y, Lian J, Yang H, Li F, Zhao S, et al. TNF-\u03b1-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J Transl Med. 2019;17(1):165.","journal-title":"J Transl Med"},{"issue":"2","key":"1202_CR129","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","volume":"29","author":"L Xu","year":"2015","unstructured":"Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29(2):635\u201341. https:\/\/doi.org\/10.1016\/j.intimp.2015.09.017.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1202_CR130","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41392-021-00825-8","volume":"6","author":"W Li","year":"2021","unstructured":"Li W, Li F, Zhang X, Lin HK, Xu C. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduct Target Ther. 2021;6(1):422.","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"1202_CR131","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963\u201374. https:\/\/doi.org\/10.1128\/MCB.05297-11.","journal-title":"Mol Cell Biol"},{"issue":"18","key":"1202_CR132","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2710","volume":"7","author":"C Zhu","year":"2021","unstructured":"Zhu C, Dixon KO, Newcomer K, Gu G, Xiao S, Zaghouani S, et al. Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion. Sci Adv. 2021;7(18):eabd2710.","journal-title":"Sci Adv"},{"issue":"9","key":"1202_CR133","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med. 2012;18(9):1394\u2013400.","journal-title":"Nat Med"},{"issue":"10","key":"1202_CR134","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur MW, Nguyen TH, Coxe MA, Miller BC, Yates KB, Gillis JE, et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019;20(10):1335\u201347.","journal-title":"Nat Immunol"},{"issue":"4","key":"1202_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107957","volume":"32","author":"M Flosbach","year":"2020","unstructured":"Flosbach M, Oberle SG, Scherer S, Zecha J, von Hoesslin M, Wiede F, et al. PTPN2 deficiency enhances programmed T cell expansion and survival capacity of activated T cells. Cell Rep. 2020;32(4):107957. https:\/\/doi.org\/10.1016\/j.celrep.2020.107957.","journal-title":"Cell Rep"},{"issue":"69","key":"1202_CR136","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm0631","volume":"7","author":"R Tang","year":"2022","unstructured":"Tang R, Acharya N, Subramanian A, Purohit V, Tabaka M, Hou Y, et al. Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Sci Immunol. 2022;7(69):eabm0631.","journal-title":"Sci Immunol"},{"issue":"1","key":"1202_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07574-4","volume":"216","author":"C Li","year":"2025","unstructured":"Li C, Fang L, Su X, Zhang J, Xiong H, Yu H, et al. Macrophage miR-4524a-5p\/TBP promotes \u03b2-TrCP -TIM3 complex activation and TGF\u03b2 release and aggravates NAFLD-associated fibrosis. Cell Death Dis. 2025;216(1):315.","journal-title":"Cell Death Dis"},{"key":"1202_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2023.107852","volume":"104","author":"G Vergoten","year":"2023","unstructured":"Vergoten G, Bailly C. N-glycosylation reinforces interaction of immune checkpoint TIM-3 with a small molecule ligand. Comput Biol Chem. 2023;104:107852. https:\/\/doi.org\/10.1016\/j.compbiolchem.2023.107852.","journal-title":"Comput Biol Chem"},{"issue":"1","key":"1202_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0752-8","volume":"11","author":"TAW Holderried","year":"2019","unstructured":"Holderried TAW, de Vos L, Bawden EG, Vogt TJ, Dietrich J, Zarbl R, et al. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clin Epigenetics. 2019;11(1):161. https:\/\/doi.org\/10.1186\/s13148-019-0752-8.","journal-title":"Clin Epigenetics"},{"key":"1202_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.584652","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Sai K, Wang XL, Ye SQ, Liang LJ, Zhou Y, et al. Tim-3 expression and MGMT methylation status association with survival in glioblastoma. Front Pharmacol. 2020;11:584652. https:\/\/doi.org\/10.3389\/fphar.2020.584652.","journal-title":"Front Pharmacol"},{"key":"1202_CR141","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12935-020-01380-y","volume":"20","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian S, Zhao M, Yang T, Quan S, Yang Q, et al. SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer. Cancer Cell Int. 2020;20:325.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1202_CR142","first-page":"2655","volume":"42","author":"L Zhang","year":"2019","unstructured":"Zhang L, Tian S, Pei M, Zhao M, Wang L, Jiang Y, et al. Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim\u20113 and galectin\u20119, in cervical cancer. Oncol Rep. 2019;42(6):2655\u201369.","journal-title":"Oncol Rep"},{"issue":"101","key":"1202_CR143","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp7302","volume":"9","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Ren C, Xiao R, Ma S, Liu H, Dou Y, et al. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol. 2024;9(101):eadp7302.","journal-title":"Sci Immunol"},{"issue":"48","key":"1202_CR144","doi-asserted-by":"publisher","first-page":"34529","DOI":"10.1074\/jbc.M113.488478","volume":"288","author":"K M\u00f6ller-Hackbarth","year":"2013","unstructured":"M\u00f6ller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, et al. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem. 2013;288(48):34529\u201344. https:\/\/doi.org\/10.1074\/jbc.M113.488478.","journal-title":"J Biol Chem"},{"issue":"8","key":"1202_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101686","volume":"5","author":"C Chen","year":"2024","unstructured":"Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024;5(8):101686. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101686.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1202_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03293-y","volume":"44","author":"I Pourmir","year":"2025","unstructured":"Pourmir I, Benhamouda N, Tran T, Roux H, Pineau J, Gey A, et al. Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2025;44(1):54. https:\/\/doi.org\/10.1186\/s13046-025-03293-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"1202_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115445","volume":"209","author":"C Bailly","year":"2023","unstructured":"Bailly C, Thuru X, Goossens L, Goossens JF. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Biochem Pharmacol. 2023;209:115445. https:\/\/doi.org\/10.1016\/j.bcp.2023.115445.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1202_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040208","volume":"10","author":"IG Zizzari","year":"2020","unstructured":"Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, et al. Soluble immune checkpoints, gut metabolites and performance status as parameters of response to Nivolumab treatment in NSCLC patients. J Pers Med. 2020;10(4):208.","journal-title":"J Pers Med"},{"key":"1202_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216300","volume":"568","author":"F Wang","year":"2023","unstructured":"Wang F, Liu S, Liu F, Xu T, Ma J, Liang J, et al. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. Cancer Lett. 2023;568:216300. https:\/\/doi.org\/10.1016\/j.canlet.2023.216300.","journal-title":"Cancer Lett"},{"issue":"5","key":"1202_CR150","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-23-0722","volume":"12","author":"J Yang","year":"2024","unstructured":"Yang J, Wang L, Byrnes JR, Kirkemo LL, Driks H, Belair CD, et al. PVRL2 suppresses antitumor immunity through PVRIG and TIGIT-independent pathways. Cancer Immunol Res. 2024;12(5):575\u201391. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0722.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1202_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40755-3","volume":"14","author":"JD Worboys","year":"2023","unstructured":"Worboys JD, Vowell KN, Hare RK, Ambrose AR, Bertuzzi M, Conner MA, et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nat Commun. 2023;14(1):5016. https:\/\/doi.org\/10.1038\/s41467-023-40755-3.","journal-title":"Nat Commun"},{"issue":"4","key":"1202_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004711","volume":"10","author":"EY Chiang","year":"2022","unstructured":"Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10(4):e004711. https:\/\/doi.org\/10.1136\/jitc-2022-004711.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1202_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108353","volume":"26","author":"KB Lupo","year":"2023","unstructured":"Lupo KB, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Cohen-Gadol AA, et al. TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. iScience. 2023;26(12):108353.","journal-title":"iScience"},{"issue":"10","key":"1202_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102712","volume":"15","author":"MF Hasan","year":"2023","unstructured":"Hasan MF, Croom-Perez TJ, Oyer JL, Dieffenthaller TA, Robles-Carrillo LD, Eloriaga JE, et al. TIGIT expression on activated NK cells correlates with greater anti-tumor activity but promotes functional decline upon lung cancer exposure: implications for adoptive cell therapy and TIGIT-targeted therapies. Cancers (Basel). 2023;15(10):2712. https:\/\/doi.org\/10.3390\/cancers15102712.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1202_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7. https:\/\/doi.org\/10.1186\/s40364-023-00543-z.","journal-title":"Biomark Res"},{"issue":"2","key":"1202_CR156","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"3","key":"1202_CR157","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu S, Zhang H, Li M, Hu D, Li C, Ge B, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20(3):456\u201364.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1202_CR158","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","volume":"54","author":"HS Jin","year":"2021","unstructured":"Jin HS, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54(1):2\u201311.","journal-title":"BMB Rep"},{"issue":"3","key":"1202_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030200","volume":"14","author":"J Yeo","year":"2021","unstructured":"Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT\/CD226 axis regulates anti-tumor immunity. Pharmaceuticals (Basel). 2021;14(3):200. https:\/\/doi.org\/10.3390\/ph14030200.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1202_CR160","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jcmgh.2021.03.003","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor PPC, Noordam L, et al. TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2021;12(2):443\u201364. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.03.003.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"1202_CR161","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O\u2019Gorman WE, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity. 2022;55(3):512-526.e9.","journal-title":"Immunity"},{"issue":"1","key":"1202_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00418-x","volume":"6","author":"J Liu","year":"2021","unstructured":"Liu J, Cheng Y, Zheng M, Yuan B, Wang Z, Li X, et al. Targeting the ubiquitination\/deubiquitination process to regulate immune checkpoint pathways. Signal Transduct Target Ther. 2021;6(1):28. https:\/\/doi.org\/10.1038\/s41392-020-00418-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"2 Pt A","key":"1202_CR163","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.molimm.2015.07.005","volume":"68","author":"DJ van den Boomen","year":"2015","unstructured":"van den Boomen DJ, Lehner PJ. Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I. Mol Immunol. 2015;68(2 Pt A):106\u201311.","journal-title":"Mol Immunol"},{"issue":"6","key":"1202_CR164","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/eji.201847848","volume":"49","author":"R Molfetta","year":"2019","unstructured":"Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, Cippitelli M, et al. The ubiquitin-proteasome pathway regulates Nectin2\/CD112 expression and impairs NK cell recognition and killing. Eur J Immunol. 2019;49(6):873\u201383. https:\/\/doi.org\/10.1002\/eji.201847848.","journal-title":"Eur J Immunol"},{"key":"1202_CR165","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbrc.2021.05.034","volume":"562","author":"YX Lin","year":"2021","unstructured":"Lin YX, Hung MC, Hsu JL, Hsu JM. The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR\/TIGIT interaction. Biochem Biophys Res Commun. 2021;562:9\u201314. https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.034.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1202_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00849-9","volume":"20","author":"Y Miao","year":"2022","unstructured":"Miao Y, Zhang C, Yang L, Zeng X, Hu Y, Xue X, et al. The activation of PPAR\u03b3 enhances Treg responses through up-regulating CD36\/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of T\u03b2RII\/IL-2R\u03b1. Cell Commun Signal. 2022;20(1):48. https:\/\/doi.org\/10.1186\/s12964-022-00849-9.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"1202_CR167","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/intimm\/dxae005","volume":"36","author":"S Tahara","year":"2024","unstructured":"Tahara S, Okumura G, Matsuo T, Shibuya A, Shibuya K. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells. Int Immunol. 2024;36(6):317\u201325. https:\/\/doi.org\/10.1093\/intimm\/dxae005.","journal-title":"Int Immunol"},{"issue":"1","key":"1202_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01270-2","volume":"14","author":"D Niebel","year":"2022","unstructured":"Niebel D, Fr\u00f6hlich A, Zarbl R, Fietz S, de Vos L, Vogt TJ, et al. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clin Epigenetics. 2022;14(1):50. https:\/\/doi.org\/10.1186\/s13148-022-01270-2.","journal-title":"Clin Epigenetics"},{"issue":"7","key":"1202_CR169","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/CJI.0000000000000429","volume":"45","author":"L de Vos","year":"2022","unstructured":"de Vos L, Carrillo Cano TM, Zarbl R, Kl\u00fcmper N, Ralser DJ, Franzen A, et al. CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA methylation is associated with BAP1-aberrancy, transcriptional activity, and overall survival in uveal melanoma. J Immunother. 2022;45(7):324\u201334. https:\/\/doi.org\/10.1097\/CJI.0000000000000429.","journal-title":"J Immunother"},{"issue":"1","key":"1202_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0539-3","volume":"10","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018;10(1):104.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1202_CR171","doi-asserted-by":"publisher","first-page":"10445","DOI":"10.1038\/s41598-017-10403-0","volume":"7","author":"B Zitti","year":"2017","unstructured":"Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, et al. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci Rep. 2017;7(1):10445.","journal-title":"Sci Rep"},{"issue":"11","key":"1202_CR172","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022;71(11):2266\u201383.","journal-title":"Gut"},{"issue":"9","key":"1202_CR173","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.4049\/jimmunol.1801359","volume":"202","author":"P Do","year":"2019","unstructured":"Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, et al. Leukemic B cell CTLA-4 suppresses costimulation of T cells. J Immunol. 2019;202(9):2806\u201316. https:\/\/doi.org\/10.4049\/jimmunol.1801359.","journal-title":"J Immunol"},{"key":"1202_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931316","volume":"13","author":"F Ghorbaninezhad","year":"2022","unstructured":"Ghorbaninezhad F, Masoumi J, Bakhshivand M, Baghbanzadeh A, Mokhtarzadeh A, Kazemi T, et al. CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro. Front Immunol. 2022;13:931316. https:\/\/doi.org\/10.3389\/fimmu.2022.931316.","journal-title":"Front Immunol"},{"issue":"6","key":"1202_CR175","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","volume":"4","author":"PS Linsley","year":"1996","unstructured":"Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4(6):535\u201343.","journal-title":"Immunity"},{"issue":"2","key":"1202_CR176","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459\u201365. https:\/\/doi.org\/10.1084\/jem.182.2.459.","journal-title":"J Exp Med"},{"issue":"6029","key":"1202_CR177","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600\u20133.","journal-title":"Science"},{"issue":"7851","key":"1202_CR178","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature. 2021;591(7851):652\u20138.","journal-title":"Nature"},{"issue":"30","key":"1202_CR179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A. 2021;118(30):e2023739118. https:\/\/doi.org\/10.1073\/pnas.2023739118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1202_CR180","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","volume":"44","author":"FA Schildberg","year":"2016","unstructured":"Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955\u201372.","journal-title":"Immunity"},{"issue":"3","key":"1202_CR181","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4049\/jimmunol.162.3.1270","volume":"162","author":"E Chuang","year":"1999","unstructured":"Chuang E, Lee KM, Robbins MD, Duerr JM, Alegre ML, Hambor JE, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol. 1999;162(3):1270\u20137. https:\/\/doi.org\/10.4049\/jimmunol.162.3.1270.","journal-title":"J Immunol"},{"issue":"2","key":"1202_CR182","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1006\/bbrc.1998.9191","volume":"249","author":"S Miyatake","year":"1998","unstructured":"Miyatake S, Nakaseko C, Umemori H, Yamamoto T, Saito T. Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD152). Biochem Biophys Res Commun. 1998;249(2):444\u20138. https:\/\/doi.org\/10.1006\/bbrc.1998.9191.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1202_CR183","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1074-7613(00)80346-5","volume":"6","author":"T Shiratori","year":"1997","unstructured":"Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isono K, Bonifacino JS, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity. 1997;6(5):583\u20139.","journal-title":"Immunity"},{"issue":"17","key":"1202_CR184","doi-asserted-by":"publisher","first-page":"9273","DOI":"10.1073\/pnas.94.17.9273","volume":"94","author":"Y Zhang","year":"1997","unstructured":"Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A. 1997;94(17):9273\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5265","key":"1202_CR185","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1126\/science.272.5265.1170","volume":"272","author":"LE Mareng\u00e8re","year":"1996","unstructured":"Mareng\u00e8re LE, Waterhouse P, Duncan GS, Mittr\u00fccker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science. 1996;272(5265):1170\u20133.","journal-title":"Science"},{"issue":"9","key":"1202_CR186","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.4049\/jimmunol.168.9.4420","volume":"168","author":"C Guntermann","year":"2002","unstructured":"Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol. 2002;168(9):4420\u20139. https:\/\/doi.org\/10.4049\/jimmunol.168.9.4420.","journal-title":"J Immunol"},{"issue":"2","key":"1202_CR187","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.0.CO;2-K","volume":"78","author":"S Chikuma","year":"2000","unstructured":"Chikuma S, Murakami M, Tanaka K, Uede T. Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4. J Cell Biochem. 2000;78(2):241\u201350.","journal-title":"J Cell Biochem"},{"issue":"1","key":"1202_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-10-23","volume":"10","author":"WA Teft","year":"2009","unstructured":"Teft WA, Chau TA, Madrenas J. Structure-function analysis of the CTLA-4 interaction with PP2A. BMC Immunol. 2009;10(1):23. https:\/\/doi.org\/10.1186\/1471-2172-10-23.","journal-title":"BMC Immunol"},{"issue":"18","key":"1202_CR189","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1158\/0008-5472.CAN-16-0342","volume":"77","author":"A Herrmann","year":"2017","unstructured":"Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H, et al. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res. 2017;77(18):5118\u201328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0342.","journal-title":"Cancer Res"},{"issue":"6246","key":"1202_CR190","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436\u201340 (AUTOIMMUNE DISEASE).","journal-title":"Science"},{"issue":"12","key":"1202_CR191","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41423-023-01093-y","volume":"20","author":"J Yu","year":"2023","unstructured":"Yu J, Cui J, Zhang X, Xu H, Chen Z, Li Y, et al. The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity. Cell Mol Immunol. 2023;20(12):1445\u201356. https:\/\/doi.org\/10.1038\/s41423-023-01093-y.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1202_CR192","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202312141","volume":"224","author":"PY Tey","year":"2025","unstructured":"Tey PY, Dufner A, Knobeloch KP, Pruneda JN, Clague MJ, Urb\u00e9 S. Rapid turnover of CTLA4 is associated with a complex architecture of reversible ubiquitylation. J Cell Biol. 2025;224(1):e202312141. https:\/\/doi.org\/10.1083\/jcb.202312141.","journal-title":"J Cell Biol"},{"issue":"2","key":"1202_CR193","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4049\/jimmunol.175.2.996","volume":"175","author":"PJ Darlington","year":"2005","unstructured":"Darlington PJ, Kirchhof MG, Criado G, Sondhi J, Madrenas J. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J Immunol. 2005;175(2):996\u20131004. https:\/\/doi.org\/10.4049\/jimmunol.175.2.996.","journal-title":"J Immunol"},{"issue":"1","key":"1202_CR194","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cell.2007.01.049","volume":"129","author":"KS Lau","year":"2007","unstructured":"Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129(1):123\u201334. https:\/\/doi.org\/10.1016\/j.cell.2007.01.049.","journal-title":"Cell"},{"issue":"6","key":"1202_CR195","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.4161\/mabs.36313","volume":"6","author":"L Zhu","year":"2014","unstructured":"Zhu L, Guo Q, Guo H, Liu T, Zheng Y, Gu P, et al. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. MAbs. 2014;6(6):1474\u201385. https:\/\/doi.org\/10.4161\/mabs.36313.","journal-title":"MAbs"},{"key":"1202_CR196","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1016\/j.csbj.2020.11.037","volume":"18","author":"Y Song","year":"2020","unstructured":"Song Y, Qian Y, Huang Z, Khattak SF, Li ZJ. Computational insights into O-glycosylation in a CTLA4 Fc-fusion protein linker and its impact on protein quality attributes. Comput Struct Biotechnol J. 2020;18:3925\u201335. https:\/\/doi.org\/10.1016\/j.csbj.2020.11.037.","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"1202_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107241","volume":"300","author":"RA Mariuzza","year":"2024","unstructured":"Mariuzza RA, Shahid S, Karade SS. The immune checkpoint receptor LAG3: structure, function, and target for cancer immunotherapy. J Biol Chem. 2024;300(5):107241. https:\/\/doi.org\/10.1016\/j.jbc.2024.107241.","journal-title":"J Biol Chem"},{"issue":"805","key":"1202_CR198","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adg2610","volume":"16","author":"K Aigner-Radakovics","year":"2023","unstructured":"Aigner-Radakovics K, De Sousa Linhares A, Salzer B, Lehner M, Izadi S, Castilho A, et al. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif. Sci Signal. 2023;16(805):eadg2610.","journal-title":"Sci Signal"},{"issue":"10","key":"1202_CR199","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392\u20135. https:\/\/doi.org\/10.4049\/jimmunol.169.10.5392.","journal-title":"J Immunol"},{"issue":"6","key":"1202_CR200","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.4049\/jimmunol.1401025","volume":"193","author":"J Bae","year":"2014","unstructured":"Bae J, Lee SJ, Park CG, Lee YS, Chun T. Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol. 2014;193(6):3101\u201312. https:\/\/doi.org\/10.4049\/jimmunol.1401025.","journal-title":"J Immunol"},{"issue":"5","key":"1202_CR201","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022;23(5):757\u201367.","journal-title":"Nat Immunol"},{"issue":"7","key":"1202_CR202","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/jid.2014.29","volume":"134","author":"C Camisaschi","year":"2014","unstructured":"Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol. 2014;134(7):1893\u2013902. https:\/\/doi.org\/10.1038\/jid.2014.29.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1202_CR203","doi-asserted-by":"publisher","first-page":"e0023025","DOI":"10.1128\/mbio.00230-25","volume":"16","author":"H Ge","year":"2025","unstructured":"Ge H, Guo N, Liu Y, Lang B, Yin X, Yu X, et al. The inhibitory receptor LAG3 affects NK cell IFN-\u03b3 production through glycolysis and the PSAT1\/STAT1\/IFNG pathway. MBio. 2025;16(6):e0023025.","journal-title":"MBio"},{"issue":"15","key":"1202_CR204","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1074\/jbc.RA119.007455","volume":"294","author":"TK Maeda","year":"2019","unstructured":"Maeda TK, Sugiura D, Okazaki IM, Maruhashi T, Okazaki T. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. J Biol Chem. 2019;294(15):6017\u201326. https:\/\/doi.org\/10.1074\/jbc.RA119.007455.","journal-title":"J Biol Chem"},{"key":"1202_CR205","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.686395","volume":"9","author":"L Zhou","year":"2021","unstructured":"Zhou L, Ge Y, Fu Y, Wu B, Zhang Y, Li L, et al. Global screening of LUBAC and OTULIN interacting proteins by human proteome microarray. Front Cell Dev Biol. 2021;9:686395. https:\/\/doi.org\/10.3389\/fcell.2021.686395.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1202_CR206","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.cell.2025.02.014","volume":"188","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Dai A, Huang Y, Li H, Cui J, Yang H, et al. Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell. 2025;188(9):2354-2371.e18.","journal-title":"Cell"},{"issue":"4","key":"1202_CR207","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3(4):412\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0150.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1202_CR208","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.176.2.327","volume":"176","author":"E Baixeras","year":"1992","unstructured":"Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327\u201337.","journal-title":"J Exp Med"},{"issue":"11","key":"1202_CR209","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.4049\/jimmunol.173.11.6806","volume":"173","author":"N Li","year":"2004","unstructured":"Li N, Workman CJ, Martin SM, Vignali DA. Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol. 2004;173(11):6806\u201312. https:\/\/doi.org\/10.4049\/jimmunol.173.11.6806.","journal-title":"J Immunol"},{"issue":"2","key":"1202_CR210","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","volume":"26","author":"N Li","year":"2007","unstructured":"Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 2007;26(2):494\u2013504.","journal-title":"EMBO J"},{"issue":"49","key":"1202_CR211","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc2728","volume":"5","author":"LP Andrews","year":"2020","unstructured":"Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, et al. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020;5(49):eabc2728.","journal-title":"Sci Immunol"},{"key":"1202_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754961","volume":"12","author":"M Guo","year":"2021","unstructured":"Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z, et al. Serum LAG-3 predicts outcome and treatment response in hepatocellular carcinoma patients with transarterial chemoembolization. Front Immunol. 2021;12:754961. https:\/\/doi.org\/10.3389\/fimmu.2021.754961.","journal-title":"Front Immunol"},{"issue":"1","key":"1202_CR213","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0810-y","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J Immunother Cancer. 2019;7(1):334. https:\/\/doi.org\/10.1186\/s40425-019-0810-y.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1202_CR214","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/CBM-181278","volume":"23","author":"N Li","year":"2018","unstructured":"Li N, Jilisihan B, Wang W, Tang Y, Keyoumu S. Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-\u03b3 in peripheral blood. Cancer Biomark. 2018;23(3):341\u201351.","journal-title":"Cancer Biomark"},{"issue":"6","key":"1202_CR215","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41416-023-02558-7","volume":"130","author":"J Gorgulho","year":"2024","unstructured":"Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Br\u00fcmmendorf TH, Loosen SH, et al. Soluble lymphocyte activation gene-3 (sLAG3) and CD4\/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies. Br J Cancer. 2024;130(6):1013\u201322.","journal-title":"Br J Cancer"},{"issue":"7","key":"1202_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070651","volume":"11","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, et al. The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study. J Pers Med. 2021;11(7):651. https:\/\/doi.org\/10.3390\/jpm11070651.","journal-title":"J Pers Med"},{"issue":"11","key":"1202_CR217","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","volume":"56","author":"RJ Zhang","year":"2024","unstructured":"Zhang RJ, Kim TK. VISTA-mediated immune evasion in cancer. Exp Mol Med. 2024;56(11):2348\u201356. https:\/\/doi.org\/10.1038\/s12276-024-01336-6.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1202_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00501-x","volume":"13","author":"Y Lin","year":"2024","unstructured":"Lin Y, Choukrani G, Dubbel L, Rockstein L, Freile JA, Qi Y, et al. VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses. Exp Hematol Oncol. 2024;13(1):35. https:\/\/doi.org\/10.1186\/s40164-024-00501-x.","journal-title":"Exp Hematol Oncol"},{"issue":"29","key":"1202_CR219","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adm8660","volume":"10","author":"I Vanmeerbeek","year":"2024","unstructured":"Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, et al. Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci Adv. 2024;10(29):eadm8660.","journal-title":"Sci Adv"},{"issue":"3","key":"1202_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189351","volume":"1880","author":"X Niu","year":"2025","unstructured":"Niu X, Li B, Luo F, Li W, Zhou X, Zhao W. Vista as a context-dependent immune checkpoint: implications for tumor immunity and autoimmune pathogenesis. Biochim Biophys Acta (BBA). 2025;1880(3):189351. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189351.","journal-title":"Biochim Biophys Acta (BBA)"},{"issue":"6475","key":"1202_CR221","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0524","volume":"367","author":"MA ElTanbouly","year":"2020","unstructured":"ElTanbouly MA, Zhao Y, Nowak E, Li J, Schaafsma E, Le Mercier I, et al. VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance. Science. 2020;367(6475):eaay0524.","journal-title":"Science"},{"issue":"3","key":"1202_CR222","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00262-025-03955-y","volume":"74","author":"X Niu","year":"2025","unstructured":"Niu X, Zhao W, Zhou X, Luo F, Xiao Y, Luo T, et al. Chidamide functions as a VISTA\/PSGL-1 blocker for cancer immunotherapy. Cancer Immunol Immunother. 2025;74(3):104.","journal-title":"Cancer Immunol Immunother"},{"issue":"7779","key":"1202_CR223","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370.","journal-title":"Nature"},{"issue":"95","key":"1202_CR224","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi7418","volume":"9","author":"HM Ta","year":"2024","unstructured":"Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, et al. Lrig1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. Sci Immunol. 2024;9(95):eadi7418.","journal-title":"Sci Immunol"},{"issue":"9","key":"1202_CR225","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","volume":"7","author":"W Xu","year":"2019","unstructured":"Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunol Res. 2019;7(9):1497\u2013510. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0489.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1202_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113661","volume":"43","author":"K Zhang","year":"2024","unstructured":"Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, et al. Vista promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Rep. 2024;43(1):113661. https:\/\/doi.org\/10.1016\/j.celrep.2023.113661.","journal-title":"Cell Rep"},{"issue":"1","key":"1202_CR227","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","volume":"23","author":"N Shekari","year":"2023","unstructured":"Shekari N, Shanehbandi D, Kazemi T, Zarredar H, Baradaran B, Jalali SA, et al. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. Cancer Cell Int. 2023;23(1):265.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"1202_CR228","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","volume":"28","author":"N Mehta","year":"2019","unstructured":"Mehta N, Maddineni S, Mathews II, Andres Parra Sperberg R, Huang PS, Cochran JR. Structure and functional binding epitope of V-domain Ig suppressor of T cell activation. Cell Rep. 2019;28(10):2509-2516.e5.","journal-title":"Cell Rep"},{"issue":"1","key":"1202_CR229","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41590-019-0563-2","volume":"21","author":"KM Mahoney","year":"2020","unstructured":"Mahoney KM, Freeman GJ. Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2020;21(1):13\u20136.","journal-title":"Nat Immunol"},{"key":"1202_CR230","doi-asserted-by":"publisher","first-page":"23938","DOI":"10.1038\/srep23938","volume":"6","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Gao WW, Tang HM, Deng JJ, Wong CM, Chan CP, et al. \u03b2-TrCP-mediated ubiquitination and degradation of liver-enriched transcription factor CREB-H. Sci Rep. 2016;6:23938.","journal-title":"Sci Rep"},{"issue":"460","key":"1202_CR231","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aah4117","volume":"10","author":"K Shimizu","year":"2017","unstructured":"Shimizu K, Fukushima H, Ogura K, Lien EC, Nihira NT, Zhang J, et al. The SCF\u03b2-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. 2017;10(460):eaah4117.","journal-title":"Sci Signal"},{"issue":"4","key":"1202_CR232","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1007\/s12035-024-04572-z","volume":"62","author":"Y Xu","year":"2025","unstructured":"Xu Y, Zhu Y, Shi Y, Ye B, Bo L, Tao T. Immune checkpoint VISTA negatively regulates microglia glycolysis and activation via TRIM28-mediated ubiquitination of HK2 in sepsis-associated encephalopathy. Mol Neurobiol. 2025;62(4):4452\u201365.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"1202_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110587","volume":"27","author":"M Emaldi","year":"2024","unstructured":"Emaldi M, Alamillo-Maeso P, Rey-Iborra E, Mosteiro L, Lecumberri D, Pulido R, et al. A functional role for glycosylated B7-H5\/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma. iScience. 2024;27(9):110587.","journal-title":"iScience"},{"issue":"12","key":"1202_CR234","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/glia.23517","volume":"66","author":"M Borggrewe","year":"2018","unstructured":"Borggrewe M, Grit C, Den Dunnen WFA, Burm SM, Bajramovic JJ, Noelle RJ, et al. VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases. Glia. 2018;66(12):2645\u201358.","journal-title":"Glia"},{"issue":"48","key":"1202_CR235","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq8122","volume":"10","author":"AM Abdrabou","year":"2024","unstructured":"Abdrabou AM, Ahmed SU, Fan MJ, Duong BTV, Chen K, Lo PY, et al. Identification of VISTA regulators in macrophages mediating cancer cell survival. Sci Adv. 2024;10(48):eadq8122.","journal-title":"Sci Adv"},{"key":"1202_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116231","volume":"268","author":"K Wojciechowicz","year":"2024","unstructured":"Wojciechowicz K, Spodzieja M, Wardowska A. The BTLA-HVEM complex-the future of cancer immunotherapy. Eur J Med Chem. 2024;268:116231. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116231.","journal-title":"Eur J Med Chem"},{"key":"1202_CR237","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654960","volume":"12","author":"Z Ning","year":"2021","unstructured":"Ning Z, Liu K, Xiong H. Roles of BTLA in immunity and immune disorders. Front Immunol. 2021;12:654960. https:\/\/doi.org\/10.3389\/fimmu.2021.654960.","journal-title":"Front Immunol"},{"issue":"7","key":"1202_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110253","volume":"27","author":"MZ Arifin","year":"2024","unstructured":"Arifin MZ, Leitner J, Egan D, Waidhofer-S\u00f6llner P, Kolch W, Zhernovkov V, et al. BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes. iScience. 2024;27(7):110253.","journal-title":"iScience"},{"issue":"6","key":"1202_CR239","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201905085","volume":"219","author":"X Xu","year":"2020","unstructured":"Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219(6):e201905085. https:\/\/doi.org\/10.1083\/jcb.201905085.","journal-title":"J Cell Biol"},{"issue":"1","key":"1202_CR240","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/iid3.390","volume":"9","author":"HJ Hwang","year":"2021","unstructured":"Hwang HJ, Lee JJ, Kang SH, Suh JK, Choi ES, Jang S, et al. The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood \u03b3\u03b4 T cells. Immunity Inflamm Dis. 2021;9(1):274\u201387. https:\/\/doi.org\/10.1002\/iid3.390.","journal-title":"Immunity Inflamm Dis"},{"key":"1202_CR241","unstructured":"Antibodies specific to glycosylated BTLA. WO2017096017A1. 2017."},{"issue":"47","key":"1202_CR242","doi-asserted-by":"publisher","first-page":"39553","DOI":"10.1074\/jbc.M507629200","volume":"280","author":"DM Compaan","year":"2005","unstructured":"Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem. 2005;280(47):39553\u201361.","journal-title":"J Biol Chem"},{"issue":"9","key":"1202_CR243","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.4049\/jimmunol.2300568","volume":"213","author":"H Mkhikian","year":"2024","unstructured":"Mkhikian H, Zhou RW, Saryan H, S\u00e1nchez CD, Balakrishnan A, Dang J, et al. N-glycan branching regulates BTLA opposite to PD-1 to limit T cell hyperactivity induced by branching deficiency. J Immunol. 2024;213(9):1329\u201337.","journal-title":"J Immunol"},{"key":"1202_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115161","volume":"165","author":"K Kuncewicz","year":"2023","unstructured":"Kuncewicz K, Bojko M, Battin C, Karczy\u0144ska A, Sieradzan A, Sikorska E, et al. BTLA-derived peptides as inhibitors of BTLA\/HVEM complex formation - design, synthesis and biological evaluation. Biomed Pharmacother. 2023;165:115161. https:\/\/doi.org\/10.1016\/j.biopha.2023.115161.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1202_CR245","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.immuni.2020.07.008","volume":"53","author":"MA Morrissey","year":"2020","unstructured":"Morrissey MA, Kern N, Vale RD. CD47 ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis. Immunity. 2020;53(2):290-302.e6.","journal-title":"Immunity"},{"issue":"4","key":"1202_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109546","volume":"27","author":"C Zimarino","year":"2024","unstructured":"Zimarino C, Moody W, Davidson SE, Munir H, Shields JD. Disruption of CD47-SIRP\u03b1 signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells. iScience. 2024;27(4):109546.","journal-title":"iScience"},{"issue":"1","key":"1202_CR247","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00587-3","volume":"13","author":"K Chen","year":"2024","unstructured":"Chen K, Li Y, Ni J, Yang X, Zhou Y, Pang Y, et al. Identification of a novel subtype of SPP1+\u2009macrophages expressing SIRP\u03b1: implications for tumor immune evasion and treatment response prediction. Exp Hematol Oncol. 2024;13(1):119. https:\/\/doi.org\/10.1186\/s40164-024-00587-3.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1202_CR248","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s43018-023-00691-z","volume":"5","author":"C Huang","year":"2024","unstructured":"Huang C, Wang X, Wang Y, Feng Y, Wang X, Chen S, et al. Sirp\u03b1 on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47. Nat Cancer. 2024;5(3):500\u201316. https:\/\/doi.org\/10.1038\/s43018-023-00691-z.","journal-title":"Nat Cancer"},{"issue":"1","key":"1202_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23442-z","volume":"12","author":"Z Bian","year":"2021","unstructured":"Bian Z, Shi L, Kidder K, Zen K, Garnett-Benson C, Liu Y. Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat Commun. 2021;12(1):3229. https:\/\/doi.org\/10.1038\/s41467-021-23442-z.","journal-title":"Nat Commun"},{"issue":"10","key":"1202_CR250","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41423-024-01208-z","volume":"21","author":"Y Sakano","year":"2024","unstructured":"Sakano Y, Sakano K, Hurrell BP, Shafiei-Jahani P, Kazemi MH, Li X, et al. SIRP\u03b1 engagement regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism. Cell Mol Immunol. 2024;21(10):1158\u201374. https:\/\/doi.org\/10.1038\/s41423-024-01208-z.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"1202_CR251","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1245\/s10434-022-13058-y","volume":"30","author":"T Tomiyama","year":"2023","unstructured":"Tomiyama T, Itoh S, Iseda N, Toshida K, Kosai-Fujimoto Y, Tomino T, et al. Clinical significance of signal regulatory protein alpha (SIRP\u03b1) expression in hepatocellular carcinoma. Ann Surg Oncol. 2023;30(6):3378\u201389. https:\/\/doi.org\/10.1245\/s10434-022-13058-y.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1202_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01472-4","volume":"9","author":"K Ji","year":"2023","unstructured":"Ji K, Zhang Y, Jiang S, Sun L, Zhang B, Hu D, et al. SIRP\u03b1 blockade improves the antitumor immunity of radiotherapy in colorectal cancer. Cell Death Discov. 2023;9(1):180. https:\/\/doi.org\/10.1038\/s41420-023-01472-4.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1202_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00418-4","volume":"7","author":"H Al-Sudani","year":"2023","unstructured":"Al-Sudani H, Ni Y, Jones P, Karakilic H, Cui L, Johnson LDS, et al. Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. NPJ Precis Oncol. 2023;7(1):69. https:\/\/doi.org\/10.1038\/s41698-023-00418-4.","journal-title":"NPJ Precis Oncol"},{"issue":"52","key":"1202_CR254","doi-asserted-by":"publisher","first-page":"31113","DOI":"10.1074\/jbc.M115.682914","volume":"290","author":"JD Londino","year":"2015","unstructured":"Londino JD, Gulick D, Isenberg JS, Mallampalli RK. Cleavage of signal regulatory protein \u03b1 (SIRP\u03b1) enhances inflammatory signaling. J Biol Chem. 2015;290(52):31113\u201325. https:\/\/doi.org\/10.1074\/jbc.M115.682914.","journal-title":"J Biol Chem"},{"issue":"702","key":"1202_CR255","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abb3966","volume":"14","author":"L Shi","year":"2021","unstructured":"Shi L, Kidder K, Bian Z, Chiang SKT, Ouellette C, Liu Y. SIRP\u03b1 sequesters SHP-2 to promote IL-4 and IL-13 signaling and the alternative activation of macrophages. Sci Signal. 2021;14(702):eabb3966.","journal-title":"Sci Signal"},{"issue":"5","key":"1202_CR256","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.4049\/jimmunol.2100266","volume":"207","author":"L Shi","year":"2021","unstructured":"Shi L, Bian Z, Kidder K, Liang H, Liu Y. Non-Lyn Src family kinases activate SIRP\u03b1-SHP-1 to inhibit PI3K-Akt2 and dampen proinflammatory macrophage polarization. J Immunol. 2021;207(5):1419\u201327. https:\/\/doi.org\/10.4049\/jimmunol.2100266.","journal-title":"J Immunol"},{"issue":"5","key":"1202_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114249","volume":"43","author":"B Qian","year":"2024","unstructured":"Qian B, Lu R, Mao S, Chen Y, Yang M, Zhang W, et al. Podocyte SIRP\u03b1 reduction aggravates lupus nephritis via promoting T cell inflammatory responses. Cell Rep. 2024;43(5):114249. https:\/\/doi.org\/10.1016\/j.celrep.2024.114249.","journal-title":"Cell Rep"},{"issue":"5","key":"1202_CR258","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3724\/abbs.2024198","volume":"57","author":"Y Xia","year":"2024","unstructured":"Xia Y, Zhao Y, Tian J, Yang X, Fan Y, Dong S, et al. SIRP\u03b1 modulates the podocyte cytoskeleton through influencing the phosphorylation of FAK at tyrosine residue 597. Acta Biochim Biophys Sin (Shanghai). 2024;57(5):782\u201391.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"3","key":"1202_CR259","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00571.2009","volume":"299","author":"H Kurihara","year":"2010","unstructured":"Kurihara H, Harita Y, Ichimura K, Hattori S, Sakai T. SIRP-alpha-CD47 system functions as an intercellular signal in the renal glomerulus. Am J Physiol Renal Physiol. 2010;299(3):F517\u201327.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"1202_CR260","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350375","volume":"53","author":"Y Feng","year":"2023","unstructured":"Feng Y, Huang C, Wang Y, Chen J. SIRP\u03b1: a key player in innate immunity. Eur J Immunol. 2023;53(11):e2350375. https:\/\/doi.org\/10.1002\/eji.202350375.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1202_CR261","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-025-59621-5","volume":"16","author":"P Dai","year":"2025","unstructured":"Dai P, Sun Y, Huang Z, Liu YT, Gao M, Liu HM, et al. USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity. Nat Commun. 2025;16(1):4564.","journal-title":"Nat Commun"},{"issue":"27","key":"1202_CR262","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206380","volume":"10","author":"L Du","year":"2023","unstructured":"Du L, Su Z, Wang S, Meng Y, Xiao F, Xu D, et al. EGFR-induced and c-Src-mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion. Adv Sci. 2023;10(27):e2206380. https:\/\/doi.org\/10.1002\/advs.202206380.","journal-title":"Adv Sci"},{"issue":"9","key":"1202_CR263","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cac2.70040","volume":"45","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zhang C, Zang R, Chen W, Guo Y, Jiang H, et al. Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47. Cancer Commun. 2025;45(9):1090\u2013112. https:\/\/doi.org\/10.1002\/cac2.70040.","journal-title":"Cancer Commun"},{"issue":"5","key":"1202_CR264","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412205","volume":"12","author":"Q Gou","year":"2025","unstructured":"Gou Q, Yan B, Duan Y, Guo Y, Qian J, Shi J, et al. Ubiquitination of CD47 regulates innate anti-tumor immune response. Adv Sci. 2025;12(5):e2412205. https:\/\/doi.org\/10.1002\/advs.202412205.","journal-title":"Adv Sci"},{"issue":"49","key":"1202_CR265","doi-asserted-by":"publisher","first-page":"37953","DOI":"10.1074\/jbc.M110.180018","volume":"285","author":"WY Lee","year":"2010","unstructured":"Lee WY, Weber DA, Laur O, Stowell SR, McCall I, Andargachew R, et al. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47. J Biol Chem. 2010;285(49):37953\u201363.","journal-title":"J Biol Chem"},{"issue":"5","key":"1202_CR266","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.237800","volume":"133","author":"BH Hayes","year":"2020","unstructured":"Hayes BH, Tsai RK, Dooling LJ, Kadu S, Lee JY, Pantano D, et al. Macrophages show higher levels of engulfment after disruption of cis interactions between CD47 and the checkpoint receptor SIRP\u03b1. J Cell Sci. 2020;133(5):jcs237800.","journal-title":"J Cell Sci"},{"issue":"9","key":"1202_CR267","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/db24-0008","volume":"73","author":"KA Leslie","year":"2024","unstructured":"Leslie KA, Lekka C, Richardson SJ, Russell MA, Morgan NG. Regulation of STAT1 signaling in human pancreatic \u03b2-cells by the lysine deacetylase HDAC6: a new therapeutic opportunity in Type 1 diabetes? Diabetes. 2024;73(9):1473\u201385. https:\/\/doi.org\/10.2337\/db24-0008.","journal-title":"Diabetes"},{"issue":"1","key":"1202_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-02982-4","volume":"43","author":"M Gracia-Hernandez","year":"2024","unstructured":"Gracia-Hernandez M, Yende AS, Gajendran N, Alahmadi Z, Li X, Munoz Z, et al. Targeting HDAC6 improves anti-CD47 immunotherapy. J Exp Clin Cancer Res. 2024;43(1):60. https:\/\/doi.org\/10.1186\/s13046-024-02982-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1202_CR269","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03335-5","volume":"44","author":"X Xu","year":"2025","unstructured":"Xu X, Wang Q, Guo K, Xu J, Lu Y, Chen H, et al. CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages. J Exp Clin Cancer Res. 2025;44(1):67. https:\/\/doi.org\/10.1186\/s13046-025-03335-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1202_CR270","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111896119","volume":"119","author":"H Yu","year":"2022","unstructured":"Yu H, Luo H, Chang L, Wang S, Geng X, Kang L, et al. The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice. Proc Natl Acad Sci U S A. 2022;119(6):e2111896119. https:\/\/doi.org\/10.1073\/pnas.2111896119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1202_CR271","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162870","volume":"133","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou H, Liu P, Lv D, Shi Y, Tang B, et al. SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47\/SIRP\u03b1 axis. J Clin Invest. 2023;133(4):e162870. https:\/\/doi.org\/10.1172\/JCI162870.","journal-title":"J Clin Invest"},{"issue":"1","key":"1202_CR272","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02264-x","volume":"41","author":"A Archilla-Ortega","year":"2022","unstructured":"Archilla-Ortega A, Domuro C, Martin-Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. J Exp Clin Cancer Res. 2022;41(1):62. https:\/\/doi.org\/10.1186\/s13046-022-02264-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1202_CR273","first-page":"382","volume":"21","author":"L Chen","year":"2024","unstructured":"Chen L, Zhao X, Liu X, Ouyang Y, Xu C, Shi Y. Development of small molecule drugs targeting immune checkpoints. Cancer Biol Med. 2024;21(5):382\u201399.","journal-title":"Cancer Biol Med"},{"key":"1202_CR274","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114567","volume":"161","author":"Z Lin","year":"2023","unstructured":"Lin Z, Huang K, Guo H, Jia M, Sun Q, Chen X, et al. Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomed Pharmacother. 2023;161:114567. https:\/\/doi.org\/10.1016\/j.biopha.2023.114567.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1202_CR275","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):27. https:\/\/doi.org\/10.1186\/s43556-025-00267-6.","journal-title":"Mol Biomed"},{"issue":"11","key":"1202_CR276","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer N, Janicka N, Szlasa W, Skinderowicz B, Ko\u0142odzi\u0144ska K, Dwernicka W, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405\u201325. https:\/\/doi.org\/10.1007\/s00262-023-03516-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1202_CR277","unstructured":"Sym023 (anti-TIM-3) in patients with advanced solid tumor malignancies or lymphomas. ClinicalTrials.gov identifier: NCT03489343."},{"issue":"2","key":"1202_CR278","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99(2):E32\u20136. https:\/\/doi.org\/10.1002\/ajh.27161.","journal-title":"Am J Hematol"},{"issue":"5","key":"1202_CR279","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14737140.2021.1865814","volume":"21","author":"AM Zeidan","year":"2021","unstructured":"Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021;21(5):523\u201334. https:\/\/doi.org\/10.1080\/14737140.2021.1865814.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"1202_CR280","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf144","volume":"30","author":"ME Gutierrez","year":"2025","unstructured":"Gutierrez ME, Tang SC, Powderly JD 2nd, Balmanoukian AS, Hoyle PE, Dong Z, et al. First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. Oncologist. 2025;30(7):oyaf144.","journal-title":"Oncologist"},{"issue":"8","key":"1202_CR281","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, et al. Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody. Clin Cancer Res. 2021;27(8):2168\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4405.","journal-title":"Clin Cancer Res"},{"issue":"722","key":"1202_CR282","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6752","volume":"15","author":"S Ma","year":"2023","unstructured":"Ma S, Tian Y, Peng J, Chen C, Peng X, Zhao F, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg6752.","journal-title":"Sci Transl Med"},{"issue":"13","key":"1202_CR283","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I\/Ib clinical trial of Sabatolimab, an anti-TIM-3 antibody, alone and in combination with Spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res. 2021;27(13):3620\u20139.","journal-title":"Clin Cancer Res"},{"key":"1202_CR284","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1568664","volume":"16","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi K. Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Front Pharmacol. 2025;16:1568664. https:\/\/doi.org\/10.3389\/fphar.2025.1568664.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1202_CR285","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.str.2024.02.009","volume":"32","author":"J Sun","year":"2024","unstructured":"Sun J, Zhang X, Xue L, Cheng L, Zhang J, Chen X, et al. Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab. Structure. 2024;32(5):550-561.e5. https:\/\/doi.org\/10.1016\/j.str.2024.02.009.","journal-title":"Structure"},{"key":"1202_CR286","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010728","volume":"2","author":"W Son","year":"2025","unstructured":"Son W, Lee Y, Park Y, Park KS, Kim S, Youn H, et al. Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fc\u03b3 receptor-mediated modulation of the tumor microenvironment. J Immunother Cancer. 2025;2:e010728.","journal-title":"J Immunother Cancer"},{"issue":"8004","key":"1202_CR287","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature. 2024;627(8004):646\u201355.","journal-title":"Nature"},{"key":"1202_CR288","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70212","volume":"4","author":"G Srikanth","year":"2025","unstructured":"Srikanth G, Beda DP, Dwivedi AR, Duddukuri NK, Nanduri S, Patel J. Promising new anti-TIGIT agents: stealthy allies in cancer immunotherapy. Clin Transl Sci. 2025;4:e70212.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1202_CR289","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/jpm14010068","volume":"14","author":"N Fuchs","year":"2024","unstructured":"Fuchs N, Zhang L, Calvo-Barreiro L, Kuncewicz K, Gabr M. Inhibitors of immune checkpoints: small molecule-and peptide-based approaches. J Pers Med. 2024;14(1):68.","journal-title":"J Pers Med"},{"issue":"1","key":"1202_CR290","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12964-020-00638-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Du J, Wang H, Chen C, Jiao L, Cheng X, et al. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT\/PVR. Cell Commun Signal. 2020;18(1):142.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"1202_CR291","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s11427-023-2472-4","volume":"67","author":"X Zhou","year":"2024","unstructured":"Zhou X, Li Y, Zhang X, Li B, Jin S, Wu M, et al. Hemin blocks TIGIT\/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy. Sci China Life Sci. 2024;67(5):996\u20131009.","journal-title":"Sci China Life Sci"},{"issue":"5","key":"1202_CR292","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/biom11050706","volume":"11","author":"X Zhou","year":"2021","unstructured":"Zhou X, Jiao L, Qian Y, Dong Q, Sun Y, Zheng WV, et al. Repositioning azelnidipine as a dual inhibitor targeting CD47\/SIRP\u03b1 and TIGIT\/PVR pathways for cancer immuno-therapy. Biomolecules. 2021;11(5):706.","journal-title":"Biomolecules"},{"issue":"1","key":"1202_CR293","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","volume":"15","author":"G Shaw","year":"2022","unstructured":"Shaw G, Cavalcante L, Giles FJ, Taylor A. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells. J Hematol Oncol. 2022;15(1):134.","journal-title":"J Hematol Oncol"},{"key":"1202_CR294","doi-asserted-by":"publisher","first-page":"116162","DOI":"10.1016\/j.bcp.2024.116162","volume":"223","author":"Y Li","year":"2024","unstructured":"Li Y, Li B, Wang Q, Zhang X, Zhang Q, Zhou X, et al. Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy. Biochem Pharmacol. 2024;223:116162.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1202_CR295","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-022-00817-0","volume":"23","author":"D Qiu","year":"2023","unstructured":"Qiu D, Liu X, Wang W, Jiang X, Wu X, Zheng J, et al. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med. 2023;23(2):165\u201374.","journal-title":"Clin Exp Med"},{"key":"1202_CR296","doi-asserted-by":"publisher","first-page":"982539","DOI":"10.3389\/fchem.2022.982539","volume":"10","author":"F Xiong","year":"2022","unstructured":"Xiong F, Yu M, Xu H, Zhong Z, Li Z, Guo Y, et al. Discovery of TIGIT inhibitors based on DEL and machine learning. Front Chem. 2022;10:982539.","journal-title":"Front Chem"},{"issue":"35","key":"1202_CR297","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.1002\/anie.202002783","volume":"59","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zuo C, Li W, Shi W, Zhou X, Wang H, et al. A novel d-peptide identified by mirror-image phage display blocks TIGIT\/PVR for cancer immunotherapy. Angew Chem Int Ed Engl. 2020;59(35):15114\u20138.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"1202_CR298","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60757-7","volume":"16","author":"D Hsiehchen","year":"2025","unstructured":"Hsiehchen D, Kainthla R, Kline H, Siglinsky E, Ahn C, Zhu H. Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial. Nat Commun. 2025;16(1):5819. https:\/\/doi.org\/10.1038\/s41467-025-60757-7.","journal-title":"Nat Commun"},{"issue":"27","key":"1202_CR299","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1080\/14796694.2024.2343272","volume":"20","author":"R Shapira-Frommer","year":"2024","unstructured":"Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, et al. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024;20(27):1983\u201391. https:\/\/doi.org\/10.1080\/14796694.2024.2343272.","journal-title":"Future Oncol"},{"key":"1202_CR300","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.943740","volume":"25","author":"A Mohammed","year":"2024","unstructured":"Mohammed A, Tang B, Sadikot S, Barmaimon G. Acute eosinophilic pneumonia induced by immune checkpoint inhibitor and anti-TIGIT therapy. Am J Case Rep. 2024;25:e943740. https:\/\/doi.org\/10.12659\/AJCR.943740.","journal-title":"Am J Case Rep"},{"issue":"12","key":"1202_CR301","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","volume":"70","author":"K Hansen","year":"2021","unstructured":"Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021;70(12):3525\u201340. https:\/\/doi.org\/10.1007\/s00262-021-02921-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1202_CR302","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2253788","volume":"15","author":"SJ Diong","year":"2023","unstructured":"Diong SJ, Jashnani A, Drake AW, Bee C, Findeisen F, Dollinger G, et al. Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT. MAbs. 2023;15(1):2253788. https:\/\/doi.org\/10.1080\/19420862.2023.2253788.","journal-title":"MAbs"},{"key":"1202_CR303","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100433","volume":"28","author":"K Shirasuna","year":"2021","unstructured":"Shirasuna K, Koelsch G, Seidel-Dugan C, Salmeron A, Steiner P, Winston WM, et al. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. Cancer Treat Res Commun. 2021;28:100433. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100433.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"1202_CR304","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01325-0","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111. https:\/\/doi.org\/10.1186\/s13045-022-01325-0.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1202_CR305","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-21-2780","volume":"28","author":"NB Mettu","year":"2022","unstructured":"Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, et al. A phase 1a\/b open-label, dose-escalation study of Etigilimab alone or in combination with Nivolumab in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2022;28(5):882\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2780.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1202_CR306","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010584","volume":"13","author":"A Naing","year":"2025","unstructured":"Naing A, McKean M, Tolcher A, Victor A, Hu P, Gao W, et al. TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial. J Immunother Cancer. 2025;13(2):e010584. https:\/\/doi.org\/10.1136\/jitc-2024-010584.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1202_CR307","doi-asserted-by":"publisher","first-page":"1725365","DOI":"10.1080\/19420862.2020.1725365","volume":"12","author":"D Li","year":"2020","unstructured":"Li D, Li J, Chu H, Wang Z. A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope. MAbs. 2020;12(1):1725365.","journal-title":"MAbs"},{"key":"1202_CR308","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s44276-023-00035-5","volume":"2","author":"N Sobhani","year":"2024","unstructured":"Sobhani N, Tardiel-Cyril DR, Chai D, Generali D, Li JR, Vazquez-Perez J, et al. Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer. BJC Rep. 2024;2:4.","journal-title":"BJC Rep"},{"issue":"5","key":"1202_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101623","volume":"8","author":"SE Al-Batran","year":"2023","unstructured":"Al-Batran SE, Mueller DW, Rafiyan MR, Kiselicki D, Atmaca A, Habibzada T, et al. A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology. ESMO Open. 2023;8(5):101623. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101623.","journal-title":"ESMO Open"},{"issue":"11","key":"1202_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100725","volume":"5","author":"MG Krebs","year":"2024","unstructured":"Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, et al. Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti-programmed cell death protein 1\/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clin Res Rep. 2024;5(11):100725. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100725.","journal-title":"JTO Clin Res Rep"},{"key":"1202_CR311","doi-asserted-by":"publisher","first-page":"1225081","DOI":"10.3389\/fonc.2023.1225081","volume":"13","author":"RJ Noelle","year":"2023","unstructured":"Noelle RJ, Lines JL, Lewis LD, Martell RE, Guillaudeux T, Lee SW, et al. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Front Oncol. 2023;13:1225081.","journal-title":"Front Oncol"},{"issue":"1","key":"1202_CR312","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1038\/s41598-020-71519-4","volume":"10","author":"N Mehta","year":"2020","unstructured":"Mehta N, Maddineni S, Kelly RL, Lee RB, Hunter SA, Silberstein JL, et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020;10(1):15171.","journal-title":"Sci Rep"},{"key":"1202_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108323","volume":"157","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Shi Y, Shao C, Tang W, Liu H, Chen J, et al. Discovery of bifunctional small molecules targeting PD-L1\/VISTA with favorable pharmacokinetics for cancer immunotherapy. Bioorg Chem. 2025;157:108323. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108323.","journal-title":"Bioorg Chem"},{"issue":"13","key":"1202_CR314","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1007\/s00259-024-06854-z","volume":"51","author":"IJG Burvenich","year":"2024","unstructured":"Burvenich IJG, Wichmann CW, McDonald AF, Guo N, Rigopoulos A, Huynh N, et al. Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. Eur J Nucl Med Mol Imaging. 2024;51(13):3863\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1202_CR315","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658488","volume":"11","author":"JI Yum","year":"2021","unstructured":"Yum JI, Hong YK. Terminating cancer by blocking VISTA as a novel immunotherapy: hasta la vista, baby. Front Oncol. 2021;11:658488.","journal-title":"Front Oncol"},{"issue":"2","key":"1202_CR316","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003382","volume":"10","author":"D Thakkar","year":"2022","unstructured":"Thakkar D, Paliwal S, Dharmadhikari B, Guan S, Liu L, Kar S, et al. Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. J Immunother Cancer. 2022;10(2):e003382. https:\/\/doi.org\/10.1136\/jitc-2021-003382.","journal-title":"J Immunother Cancer"},{"key":"1202_CR317","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1311658","volume":"14","author":"S Iadonato","year":"2023","unstructured":"Iadonato S, Ovechkina Y, Lustig K, Cross J, Eyde N, Frazier E, et al. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol. 2023;14:1311658. https:\/\/doi.org\/10.3389\/fimmu.2023.1311658.","journal-title":"Front Immunol"},{"issue":"12","key":"1202_CR318","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129945","volume":"24","author":"P Chmiel","year":"2023","unstructured":"Chmiel P, G\u0119ca K, Michalski A, K\u0142osi\u0144ska M, Kaczy\u0144ska A, Polkowski WP, et al. Vista of the future: novel immunotherapy based on the human V-Set immunoregulatory receptor for digestive system tumors. Int J Mol Sci. 2023;24(12):9945. https:\/\/doi.org\/10.3390\/ijms24129945.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1202_CR319","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4(1):699. https:\/\/doi.org\/10.1038\/s42003-021-02191-1.","journal-title":"Commun Biol"},{"issue":"1","key":"1202_CR320","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47256-x","volume":"15","author":"T Thisted","year":"2024","unstructured":"Thisted T, Smith FD, Mukherjee A, Kleschenko Y, Feng F, Jiang ZG, et al. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nat Commun. 2024;15(1):2917. https:\/\/doi.org\/10.1038\/s41467-024-47256-x.","journal-title":"Nat Commun"},{"issue":"1","key":"1202_CR321","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00556-2","volume":"12","author":"A Andrzejczak","year":"2024","unstructured":"Andrzejczak A, Karabon L. BTLA biology in cancer: from bench discoveries to clinical potentials. Biomark Res. 2024;12(1):8. https:\/\/doi.org\/10.1186\/s40364-024-00556-2.","journal-title":"Biomark Res"},{"issue":"1","key":"1202_CR322","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0744-4","volume":"7","author":"YL Chen","year":"2019","unstructured":"Chen YL, Lin HW, Chien CL, Lai YL, Sun WZ, Chen CA, et al. BTLA blockade enhances cancer therapy by inhibiting IL-6\/IL-10-induced CD19high B lymphocytes. J Immunother Cancer. 2019;7(1):313. https:\/\/doi.org\/10.1186\/s40425-019-0744-4.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1202_CR323","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01845-4","volume":"22","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-D\u00edaz R, Mart\u00ednez-P\u00e9rez A, Aguilar-Garc\u00eda C, Rodrigo JP, et al. Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy. Mol Cancer. 2023;22(1):142.","journal-title":"Mol Cancer"},{"issue":"7","key":"1202_CR324","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00262-023-03435-1","volume":"72","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde C, Lorenzo-Herrero S, Mart\u00ednez-P\u00e9rez A, Gonzalez-Rodriguez AP, Payer \u00c1R, Gonz\u00e1lez-Garc\u00eda E, et al. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. Cancer Immunol Immunother. 2023;72(7):2529\u201339. https:\/\/doi.org\/10.1007\/s00262-023-03435-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1202_CR325","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553042","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yang Y, Zeng Y, Qu Q, Shen D, Mu C, et al. B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer. Front Immunol. 2025;16:1553042. https:\/\/doi.org\/10.3389\/fimmu.2025.1553042.","journal-title":"Front Immunol"},{"issue":"1","key":"1202_CR326","doi-asserted-by":"publisher","first-page":"1956142","DOI":"10.1080\/2162402X.2021.1956142","volume":"10","author":"J Choi","year":"2021","unstructured":"Choi J, Medikonda R, Saleh L, Kim T, Pant A, Srivastava S, et al. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. Oncoimmunology. 2021;10(1):1956142.","journal-title":"Oncoimmunology"},{"key":"1202_CR327","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116675","volume":"175","author":"K Wojciechowicz","year":"2024","unstructured":"Wojciechowicz K, Kuncewicz K, Rutkowski J, Jassem J, Rodziewicz-Motowid\u0142o S, Wardowska A, et al. Targeting BTLA with the peptide inhibitor HVEM(14-39) - a new way to restore the activity of T cells in melanoma. Biomed Pharmacother. 2024;175:116675. https:\/\/doi.org\/10.1016\/j.biopha.2024.116675.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1202_CR328","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-024-01847-4","volume":"25","author":"P Guruprasad","year":"2024","unstructured":"Guruprasad P, Carturan A, Zhang Y, Cho JH, Kumashie KG, et al. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer. Nat Immunol. 2024;25(6):1020\u201332.","journal-title":"Nat Immunol"},{"key":"1202_CR329","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119150","volume":"273","author":"Z Li","year":"2021","unstructured":"Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, et al. The role of CD47-SIRP\u03b1 immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci. 2021;273:119150. https:\/\/doi.org\/10.1016\/j.lfs.2021.119150.","journal-title":"Life Sci"},{"key":"1202_CR330","doi-asserted-by":"publisher","first-page":"1513555","DOI":"10.3389\/fimmu.2025.1513555","volume":"16","author":"Q Yang","year":"2025","unstructured":"Yang Q, Shu Y, Chen Y, Qi Z, Hu S, Zhang Y, et al. Expression of SIRP\u03b1-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming. Front Immunol. 2025;16:1513555.","journal-title":"Front Immunol"},{"issue":"3","key":"1202_CR331","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/abt\/tbae022","volume":"7","author":"X Niu","year":"2024","unstructured":"Niu X, Wang C, Jiang H, Gao R, Lu Y, Guo X, et al. A pan-allelic human SIRP\u03b1-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response. Antib Ther. 2024;7(3):266\u201380. https:\/\/doi.org\/10.1093\/abt\/tbae022.","journal-title":"Antib Ther"},{"issue":"12","key":"1202_CR332","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134728","volume":"5","author":"J Liu","year":"2020","unstructured":"Liu J, Xavy S, Mihardja S, Chen S, Sompalli K, Feng D, et al. Targeting macrophage checkpoint inhibitor SIRP\u03b1 for anticancer therapy. JCI Insight. 2020;5(12):e134728. https:\/\/doi.org\/10.1172\/jci.insight.134728.","journal-title":"JCI Insight"},{"key":"1202_CR333","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/CMAR.S330908","volume":"15","author":"A Pelcovits","year":"2023","unstructured":"Pelcovits A, Ollila TA, Olszewski AJ. Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma. Cancer Manag Res. 2023;15:989\u201398.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1202_CR334","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01555-4","volume":"22","author":"S Jin","year":"2024","unstructured":"Jin S, Wang H, Li Y, Yang J, Li B, Shi P, et al. Discovery of a novel small molecule as CD47\/SIRP\u03b1 and PD-1\/PD-L1 dual inhibitor for cancer immunotherapy. Cell Commun Signal. 2024;22(1):173. https:\/\/doi.org\/10.1186\/s12964-024-01555-4.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"1202_CR335","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00545-x","volume":"12","author":"D Liu","year":"2024","unstructured":"Liu D, Che X, Wu G. Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways. Biomark Res. 2024;12(1):5. https:\/\/doi.org\/10.1186\/s40364-023-00545-x.","journal-title":"Biomark Res"},{"issue":"1","key":"1202_CR336","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ajcp\/aqab221","volume":"158","author":"X Liao","year":"2022","unstructured":"Liao X, Zhang D. HHLA2 immune checkpoint is a novel prognostic predictor in hepatocellular carcinoma. Am J Clin Pathol. 2022;158(1):62\u20139. https:\/\/doi.org\/10.1093\/ajcp\/aqab221.","journal-title":"Am J Clin Pathol"},{"key":"1202_CR337","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101112","volume":"90","author":"MA Stanczak","year":"2023","unstructured":"Stanczak MA, L\u00e4ubli H. Siglec receptors as new immune checkpoints in cancer. Mol Aspects Med. 2023;90:101112. https:\/\/doi.org\/10.1016\/j.mam.2022.101112.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"1202_CR338","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656\u201366. https:\/\/doi.org\/10.1038\/s41591-019-0374-x.","journal-title":"Nat Med"},{"key":"1202_CR339","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573365","volume":"16","author":"H Benthami","year":"2025","unstructured":"Benthami H, Zohair B, Rezouki I, Naji O, Miyara K, Ennachit S, et al. Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients. Front Immunol. 2025;16:1573365. https:\/\/doi.org\/10.3389\/fimmu.2025.1573365.","journal-title":"Front Immunol"},{"issue":"44","key":"1202_CR340","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh4379","volume":"9","author":"D Bordoloi","year":"2023","unstructured":"Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, et al. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Sci Adv. 2023;9(44):eadh4379.","journal-title":"Sci Adv"},{"issue":"10","key":"1202_CR341","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100794","volume":"13","author":"A Kula","year":"2024","unstructured":"Kula A, Koszewska D, Kot A, Dawidowicz M, Mielcarska S, Waniczek D, et al. The importance of HHLA2 in solid tumors-a review of the literature. Cells. 2024;13(10):794. https:\/\/doi.org\/10.3390\/cells13100794.","journal-title":"Cells"},{"key":"1202_CR342","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111186","volume":"126","author":"M Patwekar","year":"2024","unstructured":"Patwekar M, Sehar N, Patwekar F, Medikeri A, Ali S, Aldossri RM, et al. Novel immune checkpoint targets: a promising therapy for cancer treatments. Int Immunopharmacol. 2024;126:111186. https:\/\/doi.org\/10.1016\/j.intimp.2023.111186.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1202_CR343","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-02968-2","volume":"43","author":"G Scafetta","year":"2024","unstructured":"Scafetta G, D\u2019Alessandria C, Bartolazzi A. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. J Exp Clin Cancer Res. 2024;43(1):41.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01202-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T09:02:04Z","timestamp":1767517324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-025-01202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":343,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01202-1","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}